Publications
Kwon DH, Scheuner MT, McPhaul M, Ba EH, Sumra S, Ursem C, Walker E, Wang S, Huang FW, Aggarwal RR, Belkora J. Germline Testing for Veterans with Advanced Prostate Cancer: Concerns about Service-Connected Benefits. JNCI cancer spectrum. 2024. PMID: 39254645
Kwon DH, Scheuner MT, McPhaul M, Ba EH, Sumra S, Ursem C, Walker E, Wang S, Huang FW, Aggarwal RR, Belkora J. Germline Testing for Veterans with Advanced Prostate Cancer: Concerns about Service-Connected Benefits. JNCI cancer spectrum. 2024. PMID: 39254645
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO open. 2024. PMID: 39241495
Montauti E, Oh DY, Fong L. CD4+ T cells in antitumor immunity. Trends in cancer. 2024. PMID: 39242276
Montauti E, Oh DY, Fong L. CD4+ T cells in antitumor immunity. Trends in cancer. 2024. PMID: 39242276
Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E. Proceedings of the 1st biannual bridging the gaps in lung cancer conference. The oncologist. 2024. PMID: 39237103
Toh HC, Yang MH, Wang HM, Hsieh CY, Chitapanarux I, Ho KF, Hong RL, Ang MK, Colevas AD, Sirachainan E, Lertbutsayanukul C, Ho GF, Nadler E, Algazi A, Lulla P, Wirth LJ, Wirasorn K, Liu YC, Ang SF, Low SHJ, Tho LM, Hasbullah HH, Brenner MK, Wang WW, Ong WS, Tan SH, Horak I, Ding C, Myo A, Samol J. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. PMID: 39241963
Reece D, Diels J, Van Sanden S, Pei L, Ammann E, Heuck C, Kane C, Londhe A, Peterson S, Chari A. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma. Current medical research and opinion. 2024. PMID: 39226081
Winkler J, Tan W, Diadhiou CM, McGinnis CS, Abbasi A, Hasnain S, Durney S, Atamaniuc E, Superville D, Awni L, Lee JV, Hinrichs JH, Wagner PS, Singh N, Hein MY, Borja M, Detweiler AM, Liu SY, Nanjaraj A, Sitarama V, Rugo HS, Neff N, Gartner ZJ, Oliveira Pisco A, Goga A, Darmanis S, Werb Z. Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes. The Journal of clinical investigation. 2024. PMID: 39225101
Minter DJ, Frank AK, Pierce L, Schwartz BS, Narayana S. Learning from our patients: An exploratory study to inform the development of a case tracking dashboard for internal medicine subspecialty fellows. Medical teacher. 2024. PMID: 39222022
K.H. Natsuhara, M. Vella, S.C. Behr, L. Quintal, J. Chien, M.E. Melisko, M. Majure, G.C. Buckle, A.H. Ko, H.S. Rugo. 381P Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience. Annals of Oncology. 2024. PMID:
H. Ebrahimi, M. Shodiya, E. Maldonado, T. Othman, R. Barragan-Carrillo, X. Li, A. Rock, A. Tripathi, S.K. Pal, T.B. Dorff, A. Zhumkhawala, R. Tetens Hoeg, C. Oliai, R. Olin, M. Mei, A. Chehrazi-Raffle. 701P Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT). Annals of Oncology. 2024. PMID:
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC, CAPItello-291 study group. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology. 2024. PMID: 39214106
Cheng E, Ou FS, Gatten C, Ma C, Venook AP, Lenz HJ, O'Reilly EM, Campbell PT, Kuang C, Caan BJ, Blanke CD, Ng K, Meyerhardt JA. Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer. Journal of the National Cancer Institute. 2024. PMID: 39212617
Tsimberidou AM, Alayli FA, Okrah K, Drakaki A, Khalil DN, Kummar S, Khan SA, Hodi FS, Oh DY, Cabanski CR, Gautam S, Meier SL, Amouzgar M, Pfeiffer SM, Kageyama R, Yang E, Spasic M, Tetzlaff MT, Foo WC, Hollmann TJ, Li Y, Adamow M, Wong P, Moore JS, Velichko S, Chen RO, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey VM, O'Donnell-Tormey J, Santulli-Marotto S, Butterfield LH, Da Silva DM, Fairchild J, LaVallee TM, Padrón LJ, Sharma P. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. The Journal of experimental medicine. 2024. PMID: 39190534
Chin A, Lindsay S, Bergsland EK, Kang H. Withdrawal pain following patients discontinuing Trk inhibitors. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2024. PMID: 39191376
Chin A, Lindsay S, Bergsland EK, Kang H. Withdrawal pain following patients discontinuing Trk inhibitors. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2024. PMID: 39191376
Chen DF, Roe LT, Li Y, Borges AL, Zhang JY, Babbar P, Maji S, Stevens MGV, Correy GJ, Diolaiti ME, Smith DH, Ashworth A, Stroud RM, Kelly MJS, Bondy-Denomy J, Fraser JS. AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmid. bioRxiv : the preprint server for biology. 2024. PMID: 39253479
Correy GJ, Rachman M, Togo T, Gahbauer S, Doruk YU, Stevens M, Jaishankar P, Kelley B, Goldman B, Schmidt M, Kramer T, Ashworth A, Riley P, Shoichet BK, Renslo AR, Walters WP, Fraser JS. Extensive exploration of structure activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment merging and active learning. bioRxiv : the preprint server for biology. 2024. PMID: 39253507
Chen CT, Khanna V, Kummar S, Abdul-Karim RM, Sommerhalder D, Tolcher AW, Ueno NT, Davis SL, Orr DW, Hamilton E, Patel MR, Spira AI, Jauhari S, Florou V, Duff M, Xu R, Wang J, Barkund SR, Zhou H, Pankov A, Kong W, Jahchan NS, Jackson EL, Sun JD, Junttila MR, Multani PS, Daemen A, Chow Maneval E, Munster PN. ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Cancer Research Communications. 2024. PMID: 39177285